February 25, 2019Annals of Internal Medicine
Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease
Why the study?
While many cardiovascular risk models can estimate aspirin's benefits, few bleeding risk models exist to estimate its harms.
Population
385 191 persons aged 30 to 79 years in New Zealand primary care
Design
Prospective cohort study
Follow-up
1 619 846 person-years
Authors
Discussion
Loading...
Member takes
Implication
May inform aspirin bleeding risk assessment in primary CVD prevention; leaves open validation and outcome impact.
Structured PICO
P
Population
385,191 persons aged 30 to 79 years in New Zealand primary care whose CVD risk was assessed between 2007 and 2016, excluding those with indications/contraindications to aspirin or already receiving antiplatelet/anticoagulant therapy.
O
Outcome
Major bleeding eventssafety
A newly developed prognostic bleeding risk model can estimate the absolute bleeding harms of aspirin to guide primary prevention of CVD.
Limitations
- Hemoglobin level, platelet count, and body mass index were excluded from the main models because of high numbers of missing values
- The models were not externally validated in non-New Zealand populations
Cite This Study
Selak et al. (2019) studied this question.